FRAG 176-191 (5mg) + AOD 9604 (5mg) – Blend
$90.00
For laboratory research use only. Not for human use.
- Lyophilized peptides should be reconstituted using proper aseptic laboratory technique.
- Reconstitution must be performed using Canlab-supplied Bacteriostatic Water and handled in accordance with generally accepted research practices.
- Warranty related to reconstitution, sterility or material integrity applies only when Canlab Bacteriostatic Water is used.
- Use of third-party diluents or deviation from the provided handling guidance voids any applicable warranty.
For full handling instructions and limitations, see the Peptide Reconstitution, Research Use Only section in our Product Warranty Policy Page →
Description
What Is Fragment 176-191?
Fragment 176-191, a modified version derived from AOD9604, represents a small segment of human growth hormone (hGH) occasionally termed the “lipolytic fragment.” This designation stems from laboratory studies indicating its capability to amplify fat burning, notably observed in mice genetically engineered to possess substantial fat reserves. Extensively studied in animal models, Fragment 176-191 retains the fat-burning properties of hGH while circumventing certain other effects linked to its parent protein, such as elevating insulin-like growth factor-1 (IGF-1) levels, influencing carbohydrate metabolism adversely, impacting insulin sensitivity, stimulating long bone growth, and similar outcomes. The specific targeted actions of Fragment 176-191 render it valuable for investigating human fat metabolism and hold promise for potential development as anti-obesity medications in the future.
What is AOD9604?
AOD9604, derived from fragment 176-191, itself a modified smaller component of human growth hormone (HGH), was initially formulated as an anti-obesity medication, primarily owing to its lipolytic (fat burning) attributes. This peptide stands out due to its selective impact primarily centered on fat burning, exhibiting limited influence on other physiological aspects. Notably, it doesn’t seem to affect insulin-like growth factor-1 (IGF-1) or insulin levels, thus lacking association with promoting glucose intolerance or diabetes risk. Additionally, evidence suggests that AOD9604 doesn’t provoke the formation of antibodies in the body, as its structural similarity to HGH prevents the stimulation of an immune system response.
Additional Information
Benefits
Please review the complete product description and available supporting documentation for product-specific research information. This product is sold strictly for laboratory research use.
Mechanism of Action
Refer to the product description, certificate of analysis and applicable published research for product-specific information. No medical or therapeutic claims are made.
